SCHEMBL4388586

SCHEMBL4388586

CC(O)(c1ccccn1)C(C)(O)c1ccccn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
AHR P35869 2/20 0.45
CHRM2 P08172 1/20 0.41
BLM P54132 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
METAP1 P53582 1/20 0.40
HIF1A Q16665 1/20 0.40
DOHH Q9BU89 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CHRM3 P20309 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21742008 0.91 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL11681741 0.87 L3MBTL1 (0.57) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL10044249 0.87 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1AHRCHRM2
SCHEMBL946635 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL29965849 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL12717303 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL6921056 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL27997203 0.84 SMN1; SMN2 (0.64) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL16230664 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL10442032 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1AHRCHRM2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586893-A2 Copper plating bath and method Rohm and Haas Electronic Materials LLC (US) 2013-05-01 EP claimed
US-20040029047-A1 Micropattern forming material, micropattern forming method and method for manufacturing semiconductor device RENESAS TECHNOLOGY CORP. (JP) 2004-02-12 US claimed
EP-0957903-A4 PHARMACEUTICAL COMPOSITIONS AND METHODS CODON PHARMACEUTICALS INC (US) 2002-10-09 EP claimed
US-20020141952-A1 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues APPLIED GENETICS INCORPORATED DERMATICS 2002-10-03 US claimed
EP-0957903-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS Codon Pharmaceuticals, Inc. (US) 1999-11-24 EP claimed
US-5990177-A CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM CODON PHARMACEUTICALS, INC. (US) 1999-11-23 US claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998055085-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS CODON PHARMACEUTICALS, INC. (US) 1998-12-10 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
WO-1998011882-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS CODON PHARMACEUTICALS, INC. (US) 1998-03-26 WO claimed
CN-108884030-B Improved labeling of nucleophiles using bipyridines 安捷伦科技有限公司 2022-06-28 CN disclosed
US-8454815-B2 Plating bath and method ROHM AND HAAS ELECTRONICS MATERIALS LLC (US) 2013-06-04 US disclosed
EP-2586893-A2 Copper plating bath and method Rohm and Haas Electronic Materials LLC (US) 2013-05-01 EP disclosed
US-20130098770-A1 PLATING BATH AND METHOD ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2013-04-25 US disclosed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO disclosed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO disclosed
WO-1998011882-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS CODON PHARMACEUTICALS, INC. (US) 1998-03-26 WO disclosed
US-5009980-A Polyvinylpyridines, polyaminostyrenes and aromatic nitrogen compounds, such as bipyridines or anilines E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-04-23 US disclosed
EP-0376305-A2 Aromatic nitrogen-containing compounds as adjuvants for electrostatic liquid developers E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020141952-A1 Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues TYR, MITF, MC1R SMN1; SMN2 3675/4885L3MBTL1 864/4885AHR 443/4885
US-20130098770-A1 PLATING BATH AND METHOD AOC1, PNPO, AOC3 SMN1; SMN2 854/4885L3MBTL1 3439/4885AHR 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.